Janssen Pharmaceuticals, a subsidiary of Johnson and Johnson, headquartered in Titusville, New Jersey announced that the US Food and Drug Administration (FDA) has approved under priority review Invega Trinza for the maintenance symptom control of schezophrenia. Invega Trinza is a new injectable formulation of paliperidone palmitate that can be administered just four times a year. Paliperidone palmitate is an atypical antipsychotic indicated for the treatment of certain mental/mood disorders including schizophrenia. A long-term maintenance trial showed that 93% of patients treated with Invega Trinza did not experience a significant return of schizophrenic symptoms. Schizophrenia is a complex and chronic psychiatric disorder with symptoms that can be severe and disabling. This new treatment option will provide patients with greater independence by enabling them to focus less on taking medicine and more on other aspects of their treatment plan. Janssen anticipates that Invega Trinza will be commercially available this summer.